Momenta And Baxter To Team Up On Biosimilars As U.S. Regulatory Pathway Becomes Clearer
This article was originally published in The Pink Sheet Daily
Executive Summary
Momenta believes its biologic characterization approach combined with Baxter’s commercial expertise in biologics will put the companies’ joint effort in developing biosimilars over the top in what is poised to become a very competitive space.
You may also be interested in...
Amgen, Watson Aim To Launch First Joint Oncology Biosimilar In U.S. In 2017
The partners’ flexibility allows them, together and separately, to establish solid footholds in a still-evolving field with plenty of potential but also uncertainties.
Biosimilar User Fee Agreement Allows For Reliance On Foreign Clinical Data, FDAer Says
Agency interactions with sponsors under BsUFA are not dependent upon opening an IND. Sponsors may be able to demonstrate similarity to an FDA-licensed reference product by bridging to foreign clinical data, Associate Director for Biosimilars Leah Christl says.
Biogen Tests Biosimilars Waters In Joint Venture With Samsung
A joint venture with Korean conglomerate Samsung will be limited to making generic versions of non-Biogen products, although Samsung separately is working on a biosimilar of rituximab.